Tenderwize
Back to tender search

Open-house rebate agreement for Betahistine

AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen·Dresden, Germany·Deadline Nov 30, 2027 · 416 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Betahistin (ATC-Code nach WHO: N07CA01)

62/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

62 / 100

Complexity

58 / 100

Risk factors

Structured data says electronic submission is not allowed, while the notice says communication and transmission occur e...

The notice refers to project-room documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfrist...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Nov 30, 2027

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Nov 2027
  • Conclusion of non-exclusive rebate agreements for pharmaceutical products containing Betahistine (ATC code N07CA01).
  • Open-house participation model with contract conclusion available to all interested and eligible pharmaceutical companies during the participation period.
Show full summary

This is an open-house supply arrangement for non-exclusive pharmaceutical rebate agreements for Betahistine (ATC N07CA01) with AOK PLUS. The procedure is open to all interested pharmaceutical companies that meet the stated participation conditions. No contract value is stated, minimum purchase volumes are not guaranteed, and no individual negotiations or exclusivity apply. Participation documents are available via DTVP, but the extracted procurement documents themselves were not provided for analysis.

Risks

Structured data says electronic submission is not allowed, while the notice says communication and transmission occur e...

The notice refers to project-room documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfrist...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.
  • The company must have its seat in Germany, another EU Member State, or another EEA Contracting State, as stated in the notice.
  • Local representatives may participate only if they themselves qualify as pharmaceutical companies for the offered medicines.

Buyer

Location

Dresden, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Open-house rebate agreement for Betahistine

Non-exclusive pharmaceutical rebate agreement for medicines containing Betahistine (ATC N07CA01). The lot is described as an open-house model, so any eligible pharmaceutical company may join during the participation period. No exclusivity, no individual negotiations, and no guaranteed minimum purchase volumes are stated. Performance/place of use is Germany, specifically Dresden in Saxony, according to the structured data.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Jan 2026 - Nov 2027

Category

Pharmaceutical products

Deadline

Deadline Nov 30, 2027

Procurement Details

Publication date
23 Nov 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
778877-2025

Documents (1)

Procurement document 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30